The study demonstrated a significant impact of ACM on Hb target achievement (between 10 and 12 g/dL), inappropriate ESA administration (defined as ESA use in patients with Hb levels above 12 g/dL), and severe anemia (< 9 g/dL). The gene discussed is GSTM1; the disease is anemia (phenotype).